Duke Cancer Network @DukeCancerNETWK

The Duke Cancer Network has expertise in building value-based programs that define best practices and enhance quality to best serve the needs of your community. affiliations.dukehealth.org/services/cance… United States Joined July 2016

Tweets

198
Followers

320
Following

44
Likes

3

Duke Cancer Network @DukeCancerNETWK

6 years ago

After NACT, patients who presented with cN1 disease should still receive ALND if residual disease found in LNs, but if they have pCR, their survival=cN0 pts’. Some pearls from @DrLolaFayanju on surgical management of breast cancer @DukeCancer review. #bcsm #DCR2019

0 3 5 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

Dr. Blitzblau also notes there is accumulation evidence for once weekly and one week courses of radiation therapy for breast cancer as well as more data on safety of hypofractionated nodal treatment #DCR2019

0 0 2 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

...BUT, Dr. Blitzblau also notes that other schedules are available for individual pts - elderly, limited transportation, etc #DCR2019

0 0 0 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

Dr Blitzblau @ #DCR2019: ASTRO 2018 Consensus statement of HF-WBRT expanded indications: PREFERRED dose fractionation scheme is HFWBI to dose of 4000 cGY in 15 fractions or 4250 cGY in 16 fractions for women w/ invasive br ca receiving WBI w/wo inclusion of low axilla....

0 0 0 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

Dr Sarah Sammons notes top recent wins in breast cancer: 4. OS benefit for pre/perimenopausal women with ribociclib + endocrine Rx in 1st line ER+/HER2- advanced disease #DCR2019

0 0 0 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

Dr Sarah Sammons notes top recent wins in breast cancer: 3. T-DM1 in early stage HER2+ breast cancer with residual disease post Neoadj chemo #DCR2019

0 0 0 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

Dr Sarah Sammons notes top recent wins in breast cancer: 2. Alpelisib (with Fulvestrant) approved for advanced PIK3CA mutant ER+/HER2- disease #DCR2019

0 0 0 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

Dr Sarah Sammons notes top recent wins in breast cancer: 1. First immunotherapy combination approved for first-line treatment in advanced PDL-1+ TNBC with OS benefit #DCR2019

0 0 0 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

Dr Sarah Sammons notes that AI + Ovarian suppression and CDK4/6 inhibitor (ribociclib) should be 1st line SOC in pre/perimenopausal ER+/HER2- Advanced Br Ca #DCR2019

0 0 0 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

Hepatic artery infusion: may double survival for unresectable pts & convert unresectable pts to resectable; adjuvant HAI can result in 10yr survival rates >60% #DCR2019

0 0 0 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

Dr. Lidsky advises that resection of CRLM in the setting of compromised livers (steatosis, cirrhosis, etc) require large volume/function remnants. Strategies to assist include: parenchymal preservation; ablation/resection; 2 stage resections; portal vein embolization #DCR2019

0 0 0 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

Dr Michael Lidsky summarizes KEY DEFINITION of unresectable colorectal liver mets: R0 resection would require removal of all 3 hepatic veins, both portal veins, or retrohepatic IVC and/or leave <2 adequately perfused/drained hepatic segments #DCR2019

0 0 0 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

Dr. Hsu reviews TRIBE2 @ASCO 2019: Confirmed superiority of FOLFIRINOX bev to FOLFIRI bev in metastatic CRC #DCR2019

0 0 0 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

Dr. Hsu encourages awareness of the Neoadjuvant Rectal Score a la NRG-GI002 @asco2019, a composite score that reflects change in stage with treatment, providing more information about efficacy than pCR alone #DCR2019

0 0 0 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

Dr David Hsu notes @asco2019 The IDEA Collaboration, pooling results of 4 trials of ADJ Chemo (FOLFOX or CAPEOX), failed to demonstrate noninferiority of 3 mos vs 6 mos FOLFOX in high risk Stage II Colon CA #DCR2019

0 0 0 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

To avoid nontherapeutic laparotomy, the determination of resectability of pancreatic cancer demands appropriate pre-op assessments with high quality imaging and interpretation essential, according to Dr Allen. Should consider staging laparoscopy and peritoneal cytology #DCR2019

0 0 0 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

Duke Surgical Oncologist, Peter Allen notes that given the lack of high level (randomized) data to guide options, the treatment plan for pancreatic cancer should be tailored to individual patient and tumor characteristics #DCR2019

0 0 0 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

Wonder how to have empathic conversations w/ pts? Try NURSE: name (the emotion), understand, respect, support, explore. @DukePallCare #DCR2019

0 0 0 0 0

Duke Cancer Network @DukeCancerNETWK

6 years ago

Pearl from Dr Galanos: “Palliative care is not: hospice, end of life care only, or the abdication of pt. It is not an either/or. You can have tx AND palliative care” #DCN2019

1 8 20 0 0

Download Image

Duke Cancer Network @DukeCancerNETWK

6 years ago

Dr. Thomas Longo reviews surgery in Bladder Ca at #DCR2019 :Robotic cystectomy surgery demonstrated in RAZOR to be noninferior to open surgery with regard to major complications, LN yield, margin status or QOL, BUT does offer less blood loss with less transfusion requirement